Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
(NASDAQ: NKTX) Delayed: 2.79 -0.07 (2.45%)
Previous Close $2.86    52 Week High $ 
Open $2.89    52 Week Low $ 
Day High $2.98    P/E N/A 
Day Low $2.78    EPS $ 
Volume 537,486